News

An international research team has deciphered a mechanism of the evolutionary arms race in human cells. The findings provide ...
BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention ...
Actithera’s radiopharma assets irreversibly bind to their targets, allowing for longer retention of the drug inside tumors.
Actithera, a radiopharmaceutical biotech pioneering precision radioligand therapies, has closed an oversubscribed Series A ...
Radiopharmaceutical biotech Actithera today announced the close of an oversubscribed $75.5 million Series A financing round.
A new player in radioligand therapies (RLTs), Norway and US-based Actithera, has arrived on the scene with $75.5 million in ...
Actithera has secured $75.5 million in an oversubscribed Series A round to support the clinical development of its lead ...
The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.
Diets rich in phosphate additives, commonly found in processed foods, can increase blood pressure by triggering a brain ...
Lantheus Holdings Inc. (NASDAQ:LNTH) is one of the most undervalued US stocks according to analysts. On June 20, Lantheus ...
A new PET/CT imaging technique that visualizes activated fibroblasts in the heart muscle enables early detection of ...
Medical Device Network on MSN19d
Telix launches new PET radiochemistry solution
Telix Pharmaceuticals has introduced a new positron emission tomography (PET) radiochemistry solution, AlFluor, based on ¹⁸F-aluminium fluoride (AlF). This platform technology is designed to improve ...